Sector: MedicalCADENCE PHARM. INC. (NASDAQ: CADX)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 218 |
Technical : | 184 |
Performance : | 255 |
Overall: | 263 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 168 |
Technical : | 278 |
Performance : | 281 |
Overall: | 285 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 163 |
Technical : | 211 |
Performance : | 278 |
Overall: | 264 |
Number of Stocks: | 306 |
Headlines
- Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
Nov 13, 2009 07:30 AM | CADX
- Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
Nov 05, 2009 04:02 PM | CADX
- Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
Oct 29, 2009 04:15 PM | CADX
- Cadence Pharmaceuticals' CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
Oct 28, 2009 06:00 PM | CADX
- Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
Oct 20, 2009 05:00 PM | CADX
- This Fall Will Be Crazy For These Biotech Stocks
Oct 16, 2009 02:55 PM | ACOR, AMGN, CADX, GTXI, THRX, XNPT
- Cadence Pharmaceuticals to Webcast October 7th Analyst Day
Sep 30, 2009 08:02 AM | CADX
- Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
Sep 29, 2009 06:30 PM | CADX
- Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
Sep 09, 2009 05:00 PM | CADX, UBS
- MIGENIX Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Jul 10, 2009 08:32 AM | CADX, MGI, UTHR
- Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
Aug 05, 2009 04:01 PM | CADX
- Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11, 2009
Aug 04, 2009 05:30 PM | CADX
- Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2009 Financial Results on August 5, 2009
Jul 29, 2009 04:02 PM | CADX
- Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
Jul 15, 2009 07:01 AM | CADX
- Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
Jun 22, 2009 08:02 AM | CADX
- Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
Jun 04, 2009 07:50 PM | CADX
- Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
May 14, 2009 07:01 AM | CADX
- Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
May 07, 2009 04:02 PM | CADX
- Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
May 05, 2009 04:16 PM | CADX
- Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
Apr 30, 2009 05:39 PM | CADX
- Form 4 Socks David A For: Nov 09 (10K)
Nov 10, 2009 08:11 PM
- Form 4 BREITMEYER JAMES B For: Nov 05 (10K)
Nov 06, 2009 07:07 PM
- Form 4 CADENCE PHARMACEUTICALS For: Oct 20 Filed by: CRAIG WILLIAM S (10K)
Oct 21, 2009 06:29 PM
- Form 4 CADENCE PHARMACEUTICALS For: Oct 16 Filed by: Schroeder Theodore R (10K)
Oct 19, 2009 06:38 PM
- Form 4 Socks David A For: Oct 12 (10K)
Oct 13, 2009 07:19 PM
- Form 4 BREITMEYER JAMES B For: Oct 01 (10K)
Oct 02, 2009 05:51 PM
- Form 4 Socks David A For: Sep 14 (10K)
Sep 15, 2009 10:43 PM
- Form 4 CADENCE PHARMACEUTICALS For: Sep 10 Filed by: GARNER CAM L (10K)
Sep 11, 2009 07:58 PM
- Form 4 BREITMEYER JAMES B For: Aug 31 (10K)
Sep 02, 2009 06:16 PM
- Form 4 AKER HAZEL M For: Aug 31 (10K)
Sep 02, 2009 06:15 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
CADX
|
Compare to S&P
|
| YTD |
26.14 %
|
4.20 %
|
| 4 Weeks |
-13.56 %
|
-14.01 %
|
| 12 Weeks |
-14.53 %
|
-19.79 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -35.29 %
|
|
EPS Growth in Last Year: 36.11 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
